Innovent Biologics Inc
HKEX:1801
Innovent Biologics Inc
HKEX:1801
Price:
82
HKD
-0.67%
Market Closed
Market Cap:
HK$142.3B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Innovent Biologics Inc
HKEX:1801
|
CN |
|
M
|
MS International PLC
LSE:MSI
|
UK |
|
Zhejiang Chenfeng Technology Co Ltd
SSE:603685
|
CN |
|
Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS
IST:GENIL.E
|
TR |
|
ASL Marine Holdings Ltd
SGX:A04
|
SG |
Cash Flow Statement
Cash Flow Statement
Innovent Biologics Inc
Innovent Biologics Inc
Currency: CNY
| Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||||||||
| Net Income |
(5 873)
|
(6 530)
|
(1 720)
|
(1 610)
|
(859)
|
(1 429)
|
(3 051)
|
(2 875)
|
(2 170)
|
(1 428)
|
(1 144)
|
(1 281)
|
(79)
|
1 211
|
|
| Depreciation & Amortization |
63
|
71
|
86
|
104
|
86
|
119
|
205
|
240
|
319
|
382
|
385
|
396
|
420
|
487
|
|
| Stock-Based Compensation |
36
|
0
|
89
|
194
|
308
|
394
|
385
|
404
|
339
|
292
|
448
|
519
|
413
|
452
|
|
| Other Non-Cash Items |
4 381
|
4 836
|
97
|
131
|
939
|
1 340
|
938
|
383
|
(312)
|
(364)
|
389
|
882
|
542
|
434
|
|
| Cash Taxes Paid |
0
|
0
|
(14)
|
(10)
|
140
|
136
|
26
|
38
|
66
|
85
|
(114)
|
(145)
|
0
|
1
|
|
| Cash Interest Paid |
33
|
39
|
41
|
43
|
46
|
58
|
79
|
98
|
105
|
115
|
128
|
130
|
122
|
122
|
|
| Change in Working Capital |
418
|
31
|
(128)
|
(111)
|
(474)
|
(609)
|
(117)
|
435
|
244
|
(325)
|
518
|
558
|
404
|
(315)
|
|
| Cash from Operating Activities |
(1 012)
N/A
|
(1 592)
-57%
|
(1 664)
-5%
|
(1 486)
+11%
|
(308)
+79%
|
(580)
-88%
|
(2 025)
-249%
|
(1 816)
+10%
|
(1 919)
-6%
|
(1 735)
+10%
|
148
N/A
|
555
+276%
|
1 287
+132%
|
1 816
+41%
|
|
| Investing Cash Flow | |||||||||||||||
| Capital Expenditures |
(313)
|
(359)
|
(366)
|
(293)
|
(522)
|
(868)
|
(1 848)
|
(1 913)
|
(1 366)
|
(1 514)
|
(1 382)
|
(1 525)
|
(1 642)
|
(1 172)
|
|
| Other Items |
1 168
|
(1 626)
|
(2 203)
|
(909)
|
(4 663)
|
(3 586)
|
(851)
|
(189)
|
(70)
|
424
|
383
|
(753)
|
477
|
1 105
|
|
| Cash from Investing Activities |
855
N/A
|
(1 985)
N/A
|
(2 569)
-29%
|
(1 202)
+53%
|
(5 185)
-331%
|
(4 454)
+14%
|
(2 698)
+39%
|
(2 102)
+22%
|
(1 435)
+32%
|
(1 090)
+24%
|
(999)
+8%
|
(2 277)
-128%
|
(1 165)
+49%
|
(67)
+94%
|
|
| Financing Cash Flow | |||||||||||||||
| Net Issuance of Common Stock |
4 319
|
3 373
|
2 175
|
4 298
|
4 662
|
6 483
|
3 951
|
10
|
2 131
|
2 142
|
2 255
|
2 253
|
84
|
79
|
|
| Net Issuance of Debt |
282
|
102
|
24
|
123
|
338
|
880
|
1 184
|
803
|
687
|
643
|
387
|
(164)
|
(730)
|
148
|
|
| Other |
(167)
|
(172)
|
(89)
|
(113)
|
(89)
|
(133)
|
(132)
|
(89)
|
74
|
128
|
(55)
|
(7)
|
39
|
75
|
|
| Cash from Financing Activities |
4 434
N/A
|
3 302
-26%
|
2 109
-36%
|
4 307
+104%
|
4 912
+14%
|
7 230
+47%
|
5 003
-31%
|
723
-86%
|
2 892
+300%
|
2 913
+1%
|
2 587
-11%
|
2 082
-20%
|
(607)
N/A
|
303
N/A
|
|
| Change in Cash | |||||||||||||||
| Effect of Foreign Exchange Rates |
64
|
22
|
25
|
67
|
(569)
|
(700)
|
(197)
|
82
|
119
|
(108)
|
(7)
|
22
|
13
|
4
|
|
| Net Change in Cash |
4 341
N/A
|
(252)
N/A
|
(2 099)
-732%
|
1 687
N/A
|
(1 150)
N/A
|
1 496
N/A
|
83
-94%
|
(3 113)
N/A
|
(343)
+89%
|
(20)
+94%
|
1 730
N/A
|
382
-78%
|
(472)
N/A
|
2 056
N/A
|
|
| Free Cash Flow | |||||||||||||||
| Free Cash Flow |
(1 325)
N/A
|
(1 951)
-47%
|
(2 030)
-4%
|
(1 778)
+12%
|
(829)
+53%
|
(1 447)
-74%
|
(3 872)
-168%
|
(3 729)
+4%
|
(3 284)
+12%
|
(3 249)
+1%
|
(1 234)
+62%
|
(969)
+21%
|
(355)
+63%
|
644
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
